Quintrio
Home

MEDICINAL CHEMICALS & BOTANICAL PRODUCTS

Biote Corp. Class A Common Stock

BTMD

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.

Last trade $0.9801
Day change +$0.0198 (+2.06%)
Day range $0.97 – $1.01
Volume 46,580
Market cap $26M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$25.96M
Price / earnings
—
Price / book
-0.4×
Price / sales
0.15×
EV / sales
0.77×
EV / EBITDA
10.64×

Profitability

Earnings per share
-$0.07
Return on assets
-1.89%
Return on equity
2.95%
Dividend yield
4.5%

Liquidity and leverage

Debt / equity
-1.84×
Current ratio
1.37×
Quick ratio
0.79×
Cash ratio
0.29×

Cash flow

Price / cash flow
1.86×
Price / free cash flow
4.24×
Free cash flow
$6.12M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BTMD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$43.33M$44.23M$44.94M$46.41M$47.96M$48.86M$48.99M$49.83M
Cost of revenue$14M$15.31M$13.98M$14.84M$13.54M$13.88M$12.61M$14.04M
Gross profit$29.33M$28.92M$30.95M$31.57M$34.42M$34.99M$36.38M$35.8M
Selling, general and administrative$26.84M$32.43M$27.79M$24.74M$26.15M$24.22M$26.69M$33.03M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$26.84M$33.07M$27.79M$24.74M$26.15M$24.22M$26.69M$33.03M
Operating income$2.49M-$4.16M$3.17M$6.83M$8.27M$10.77M$9.69M$2.77M
Interest expense-$2.12M-$2.18M$0$0-$2.73M-$2.85M$0$0
Income before taxes$1.37M-$7.13M$3.34M$5.6M$8.45M$6.08M$17.46M-$1.22M
Income taxes$796K$296K$662K$2.99M-$765K$2.15M$1.62M-$4.7M
Net income$569K-$7.43M$2.68M$2.62M$9.22M$3.93M$15.84M$3.48M
Net income attributable to common shareholders$407K-$6.56M$2.28M$1.95M$8.19M$3.19M$13.72M$3.7M
EBITDA$3.52M-$2.55M$4.15M$7.78M$9.22M$11.68M$10.55M$3.91M
Basic earnings per share$0.01-$0.23$0.07$0.06$0.26$0.10$0.44$0.10
Diluted earnings per share$0.01-$0.23$0.06$0.05$0.22$0.10$0.37$0.10

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

biote: 3 Key Takeaways for Long-Term Investors

biote reported Q3 2026 results with a 9.6% year-over-year revenue decline to $43.3 million, attributed to a January 2026 product recall that delayed clinic onboarding. Despite this, the company maintains full-year 2026 revenue guidance above $175 million. Management is deploying data analytics to support underperforming clinics, standardizing medical training to retain practitioners, and ramping up internal manufacturing at Xteria Health to restore gross margins, with early signs of procedure volume stabilization.

Zacks Investment Research

biote Corp. (BTMD) Tops Q3 Earnings Estimates

biote Corp. (BTMD) reported quarterly earnings of $0.01 per share, beating the consensus estimate of -$0.05 loss by 120%, but missed revenue expectations at $43.33 million versus the estimated $44.13 million. The stock has declined 56.9% year-to-date and carries a Zacks Rank #3 (Hold) rating. The Medical-Products industry ranks in the bottom 37% of Zacks industries.

Zacks Investment Research

Zacks.com featured highlights include Steelcase Carriage Services, biote and Acme United

The article highlights four stocks - Steelcase, Carriage Services, biote, and Acme United - that have seen rising cash flows, making them good investment options. The article emphasizes the importance of analyzing a company's cash position and net cash flow as indicators of financial health and growth potential.

Zacks Investment Research

Buy 4 Stocks With Rising Cash Flows to Enrich Your Portfolio - Zacks Investment Research

The article suggests that stocks with rising cash flows, such as Ardmore Shipping Corporation, TXO Partners, L.P., GeoPark Limited, and biote Corp., are worth buying as they have the flexibility to weather market uncertainties and support growth. The article emphasizes the importance of analyzing a company's cash-generating efficiency to assess its true financial health.

Zacks Investment Research

Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches - Zacks Investment Research

Haemonetics is benefiting from growth in its Plasma, Hospital, and Hemostasis Management segments, driven by new product launches and market share gains. The company's hospital portfolio is evolving, creating new growth opportunities. However, it faces challenges from inflationary pressures and supply chain disruptions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 1, 20071-for-10reverse split